CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
工程化增强的 CAR-T 细胞疗法用于实体瘤
英文原题：Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors.
查看英文原题
Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）-T细胞疗法在白血病和淋巴瘤中的早期临床成功以及随后获得美国食品药品监督管理局批准，证实了工程化T细胞可以成为血液系统恶性肿瘤的强大治疗方法。然而，这一成功尚未在实体瘤中重现。要使CAR-T 细胞疗法在实体瘤中安全有效，必须应对临床经验和良好对照的临床前动物模型中出现的诸多挑战。在此，我们综述了为增强实体瘤中CAR-T 细胞疗法而开发的生物工程策略的最新进展，重点关注靶向单基因扰动、基因回路设计、细胞因子工程和交互式生物材料。这些生物工程方法提供了一套独特的工具，可与CAR-T 细胞协同作用，以克服实体瘤中的障碍并实现稳健而持久的治疗效果。
展开英文摘要原文
The early clinical success and subsequent US Food and Drug Administration approval of chimeric antigen receptor (CAR)-T cell therapy for leukemia and lymphoma affirm that engineered T cells can be a powerful treatment for hematologic malignancies. Yet this success has not been replicated in solid tumors. Numerous challenges emerged from clinical experience and well-controlled preclinical animal models must be met to enable safe and efficacious CAR-T cell therapy in solid tumors.
Here, we review recent advances in bioengineering strategies developed to enhance CAR-T cell therapy in solid tumors, focusing on targeted single-gene perturbation, genetic circuits design, cytokine engineering, and interactive biomaterials. These bioengineering approaches present a unique set of tools that synergize with CAR-T cells to overcome obstacles in solid tumors and achieve robust and long-lasting therapeutic efficacy.
论文信息
- 作者
- Neeser A、Ramasubramanian R、Wang C、Ma L
- 第一作者单位
- Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia.United States
- 通讯作者单位
- The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia.United States
- 文献类型
- 综述
- 期刊
- Immuno-oncology technology2023 Sep
- 原文标识
- PubMed 37483659 · DOI 10.1016/j.iotech.2023.100385
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →